Financial Performance - Revenue for the third quarter of 2024 was RMB 2,861,505,455.47, an increase of 12.41% year-over-year[2] - Net profit attributable to shareholders for the third quarter was RMB 244,809,564.16, a decrease of 2.19% year-over-year[2] - Operating revenue reached 9,290,220,207.76 RMB, an increase from 8,500,085,529.08 RMB in the same period last year[12] - Operating costs totaled 8,295,069,270.45 RMB, up from 7,444,588,905.92 RMB[12] - Net profit attributable to the parent company's owners was 5,026,026,552.02 RMB, up from 4,520,034,984.41 RMB[11] - Operating profit for the quarter reached 1,023,122,464.97 yuan, a slight increase from 1,013,524,987.41 yuan in the previous period[13] - Net profit attributable to the parent company's shareholders was 869,652,417.71 yuan, up from 851,344,083.86 yuan in the prior period[13] - Sales revenue from goods and services reached 7,470,804,774.82 yuan, a significant rise from 5,986,375,397.51 yuan in the same period last year[14] - Basic earnings per share increased to 0.7466 yuan from 0.7281 yuan in the previous period[13] - Comprehensive income attributable to the parent company's shareholders rose to 873,223,790.05 yuan, compared to 848,248,390.43 yuan in the prior period[13] Cash Flow and Liquidity - Operating cash flow for the first nine months of 2024 was RMB 1,165,709,114.84, an increase of 37.38% year-over-year[2] - Net cash flow from financing activities was RMB -532,530,690.54, a decrease of 72.15% year-over-year, mainly due to increased stock repurchases and dividend payments[5] - Cash flow from operating activities increased to 1,165,709,114.84 yuan, compared to 848,540,440.86 yuan in the previous year[15] - Cash received from tax refunds amounted to 377,272,002.48 yuan, slightly higher than 366,708,211.74 yuan in the previous year[15] - Cash paid for goods and services increased to 5,241,010,944.55 yuan, up from 4,197,997,038.54 yuan in the prior period[15] - Cash flow from investment activities showed a net outflow of 364,538,076.21 yuan, an improvement from a net outflow of 460,801,711.33 yuan in the previous year[15] - Cash and cash equivalents at the end of the period stood at 2,735,557,535.96 yuan, up from 2,495,464,491.45 yuan at the beginning of the period[16] Assets and Liabilities - Total assets as of the end of the third quarter were RMB 13,339,366,342.08, an increase of 4.48% compared to the end of the previous year[2] - Total assets increased to 13,339,366,342.08 RMB, up from 12,767,664,072.34 RMB in the previous period[10] - Total liabilities rose to 6,751,589,006.48 RMB, compared to 6,537,246,876.10 RMB previously[10] - Owner's equity grew to 6,587,777,335.60 RMB, up from 6,230,417,196.24 RMB[11] - The company's monetary funds increased to 3,892,828,335.80 RMB at the end of the period, up from 3,580,686,915.36 RMB at the beginning of the period[9] - Accounts receivable rose to 1,762,610,761.91 RMB, compared to 1,695,032,971.13 RMB at the start of the period[9] - Inventory decreased to 1,844,380,687.82 RMB from 2,083,301,418.08 RMB at the beginning of the period[9] - Fixed assets stood at 2,866,856,667.27 RMB, down from 3,001,108,252.13 RMB at the start of the period[9] - Construction in progress increased to 767,150,754.39 RMB, up from 545,846,228.04 RMB at the beginning of the period[9] - Short-term borrowings increased to 871,965,120.77 RMB, compared to 807,796,237.52 RMB[10] - Accounts payable and advances from customers totaled 1,969,400,370.43 RMB, down from 2,013,890,900.04 RMB[10] - Intangible assets decreased to 312,410,959.01 RMB, from 319,795,853.83 RMB[10] R&D and Investments - R&D investment for the first nine months of 2024 was RMB 467,201,967.23, an increase of 5.26% year-over-year[5] - R&D expenses amounted to 467,201,967.23 RMB, a decrease from 483,755,349.59 RMB[12] - Prepayments increased by 119.94% year-over-year to RMB 565,176,702.21, mainly due to increased prepayments for materials[5] - Other non-current assets increased by 191.79% year-over-year to RMB 156,849,038.35, primarily due to increased prepayments for equipment[5] Shareholder Information - The company repurchased 10,880,000 shares, representing 0.93% of the total shares, through a dedicated securities account[7] - Hengdian Group Holding Co., Ltd. holds 28.30% of the company's shares, totaling 330,941,729 shares[7] - Zhejiang Hengdian Import & Export Co., Ltd. holds 13.39% of the company's shares, totaling 156,552,903 shares[7] - Zhejiang Hengrun Technology Co., Ltd. holds 5.10% of the company's shares, totaling 59,683,845 shares[7] - Hengdian Group Jiayuan Chemical Co., Ltd. holds 3.83% of the company's shares, totaling 44,750,178 shares[7] Government Subsidies and Returns - Government subsidies received during the third quarter amounted to RMB 19,784,103.27[3] - The weighted average return on equity for the first nine months of 2024 was 13.52%, a decrease of 1.25 percentage points year-over-year[2]

[Table_ 相关研究： DocReport] 普洛药业（000739.SZ）:持 2024-03-22 续提升研发能力，进一步提 升运营效率 普洛药业（000739.SZ）:盈 2023-10-22 利能力提升持续兑现，重视 研发与创新发展 [Table_Contacts] [Table_Page] 中报点评|化学制药 证券研究报告 [Table_Title] 普洛药业（000739.SZ） 运营效率提升加研发助力，盈利能力提升 [Table_Summary] 核心观点： ⚫ 原料药制剂一体化优势提升，不断增强企业核心竞争力。根据公司半 年报披露，公司 2024 上半年实现营业收入 64.29 亿元，同比增长 7.96%；实现归母净利润 6.25 亿元，同比增长 3.96%；实现扣非归母 净利润 6.02 亿元，同比增长 1.24%。截止至 2024 上半年末，公司共 有研发人员 1085 名，研发费用 3.15 亿元，两个 API 品种注册获批， 20 个原料药品种新递交国内外 DMF。 ⚫ 制剂业务规模效应带动盈利能力提升显著，CDMO 业务增长稳健。根 据公司半年报披露，2024 上半年，公司原料药 ...

[Table_Stock] 普洛药业（000739） 证 券 研 究 报 告 [Table_Author] 分析师: 王真真 Tel: 021 -53686246 E-mail: wangzhenzhen@shzq.co m SAC 编号: S0870524030001 联系人: 尤靖宜 Tel: 021-53686160 E-mail: youjingyi@shzq.com SAC 编号: S0870122080015 [Table_BaseInfo] 基本数据 最新收盘价（元） 14.93 12mth A 股价格区间（元） 11.04-19.32 总股本（百万股） 1,169.32 无限售 A 股/总股本 99.96% 流通市值（亿元） 174.51 公 司 点 评 [行业Table_Industry] : 医药生物 日期: shzqdatemark 2024年08月20日 [Table_QuotePic] 最近一年股票与沪深 300 比较 -34% -27% -21% -15% -9% -2% 4% 10% 16% 08/23 11/23 01/24 03/24 06/24 08/24 普洛药业 沪深3 ...

| --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

总市值（亿）： 181.13 魏赟 执业登记编码：S0760522030005 制剂放量盈利能力快速提升，制剂品种有望快速丰富。2024 年 H1 制剂 业务收入 6.8 亿元（+18.4%），毛利率 60.3%（+9.9pct）。2024 年 H1 在研、 完成验证、申报项目分别 51、9、6 个，减重降糖项目预计 2024 年四季度进 入临床，持续丰富的抗感染类、心脑血管类等制剂带来广阔的增长空间。2024 年 H1，奥司他韦、头孢地尼干混悬剂等 5 个国内制剂递交注册申请；制剂 处于大幅增的阶段，每年新立项 25 个左右。从 2026 年开始每年会有 15-20 个上市，新增制剂持续提供增长动力。头孢固体制剂、国际化高端制剂等车 间增设、建设将保障供应能力。 邮箱：weiyun@sxzq.com 化学原料药 普洛药业（000739.SZ） 买入-B(维持) 业绩符合预期，原料药、制剂、CDMO 项目持续丰富，业绩增长拐点已现 事件描述 2024 年 8 月 20 日 ，业绩加速增长 公司研究/公司快报 公司近一年市场表现 8 月 16 日，公司发布 2024 年半年报，2024 年 H1 公司收入 64 ...

[Table_Industry] [评Ta级ble：_T买itle入] （维持） 市场价格：15.57 分析师：祝嘉琦 执业证书编号：S0740519040001 电话：021-20315150 Email：zhujq@zts.com.cn [公Ta司ble盈_F利in预anc测e]及估值 指标 2022A 2023A 2024E 2025E 2026E 营业收入（百万元） 10544.91 11474.16 12716.23 14004.28 15477.21 增长率 yoy% 17.92% 8.81% 10.82% 10.13% 10.52% 净利润（百万元） 989.17 1055.34 1138.72 1271.50 1478.92 增长率 yoy% 3.52% 6.69% 7.90% 11.66% 16.31% 每股收益（元） 0.84 0.90 0.97 1.08 1.25 每股现金流量 1.13 0.88 0.75 1.07 1.23 净资产收益率 17.95% 16.96% 15.84% 15.78% 16.26% P/E 18.55 17.39 16.11 14.43 12.41 PEG 5 ...

公 司 研 究 医 药 生 物 [数据日期 Table_cominfo] 2024/08/19 收盘价 15.49 总股本(万股) 116,932 流通A股/B股(万股) 116,886/0 资产负债率(%) 53.08% 市净率(倍) 2.86 净资产收益率(加权) 9.68 12个月内最高/最低价 19.70/10.66 普洛药业 沪深300 [Table_Reportdate] 2024年08月19日 [Table_invest] 买入（维持） 报告原因：业绩点评 [证券分析师 Table_Authors] 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 伍可心 S0630522120001 wkx@longone.com.cn 联系人 付婷 futing@longone.com.cn [table_main] 投资要点 ➢ 公司2024H1业绩增长强劲。2024H1，公司实现营业收入64.29亿元，同比增长7.96%；归 母净利润6.25亿元，同比增长3.96%；扣非后归母净利润6.02亿元，同比增长1.24%。其中 Q2单季实现营业收入32.31亿元，同比增长 ...

证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |----------------|----------------------------------------------------------------| | 投资者关系活动 | | | | ■其他 （投资者电话交流会） | | 类别 | | | | （孙建、郭双喜、盖文化）浙商证券；（孙媛媛、黄翰漾、翁雨晴） | | | 兴业证券；（邓周宇、魏赟、张智勇）山西证券；（张琎、吴婉桦） | | | 中金公司；（李龙峰、侯彪、许菲菲）招商证券；（韩世通、王郑洋、 | | | 王凯旋）中信医药；（张树声、李雨蓓、祝嘉琦）中泰证券；（乔波 | | | 耀）民生证券；（孙曼萁）华西证券；（张绍辉）华福医药；（胡健 | | | 东）华创证券；（杨馥瑗）华安医药；（阮帅）开源证券；（陈辛、 | | | 李奕玮）华泰证券；（江熠暄、孔维崎）国海医药；（臧文清）平安 | | | 证券；（史慧颖）信达医药；（田鑫）广发医药；（杨天笑）西南医 | | | 药；（彭思宇、沈鹭）国信证券；（陶宸冉）国盛证券； ...

何总副总经理兼董事会秘书周总财务总监张总以及董事会办公室主任兼证券事务代表关总就昨天刚刚发布的2024年公司中报的情况跟大家做沟通和交流然后我先简单介绍一下整个2024年中报我们看到 公司当季度把收入和利润都创了历史的这个单季的新高同时在背后也验证了公司过去几年一直 跟市场传递的从做精油原料做优质剂做强CDMO整个战略的落地无论是我们原料业务过一年的稳定增长还是我们质剂业务环比快速的一个增长这个都让我们看到这句话都在快速兑现同时CDMO的报价项目也呈现了一个非常快速增长我相信这都是过一年公司从能力建设 到公司整个资本开支逐步进入一个兑现期所呈现的一个表现所以我们团队也非常看好公司未来几年持续的这么一个趋势所以也恭喜公司取得这样亮丽的夜景就是今天跟我一起主持的还有我们团队的郭双喜博士以及文化 然后首先我们进入我们今天会议的第一个环节有请普洱药业总经理何总就昨天刚刚发布的中报的情况跟大家做这个简单的一个介绍何总好的各位投资者上午好我是普洱药业何春下面由我对公司上半年的经营情况做个简单的介绍 那么从大环境来看的话上半年整个医药行业的外围环境还是比较严峻的一方面地缘政治影响还在然后行业内卷和国内价格的治理还有医药领域 ...

证券研究报告 | 公司点评 | 化学制药 | --- | --- | |-----------------------------------------------------------------|------------------------------------------| | 普洛药业 (000739) | 报告日期： 2024 年 08 月 17 日 | | 高基数下超预期，看好 H2 表现 ——普洛药业 2024H1 业绩点评 | | 投资要点 ❑ 2024Q2 公司收入&利润均创历史新高，我们认为，公司在 2020 年后进入资本开 支加速期、供给能力升级期，随着投资产能陆续进入释放期，收入结构改善 下，公司有望进入新一轮供给升级驱动的高质量增长周期。 ❑ 财务表现： Q2 收入&利润创新高 2024 年 8 月 15 日公司发布 2024 年半年报，2024H1 公司实现营业收入 64.29 亿 元，同比增长 7.96%；归母净利润为 6.25 亿元，同比增长 3.96%，扣非归母净利 润 6.02 亿元，同比增长 1.24%。单季度看，2024Q2 公司实现营业收入 32.31 亿 ...